Description

Botswana Pharmaceuticals and Healthcare Report Q4 2015

BMI View: Communicable diseases will continue to dominate Botswana's disease profile, with HIV/AIDSposing the greatest burden. The government's provision of free antiretroviral treatment will provideopportunities for generic drugmakers within the public healthcare sector. As the economy develops, theburden of non-communicable diseases will increase, providing a more attractive epidemiological profile formultinational drugmakers.

Headline Expenditure Projections

Pharmaceuticals: BWP1.80bn (USD200mn) in 2014 to BWP1.96bn (USD199mn) in 2015; +9.4% inlocal currency terms and -0.4%% in US dollar terms. Forecast in line with Q315.

Healthcare: BWP7.45bn (USD830mn) in 2014 to BWP8.21bn (USD833mn) in 2015; +10.2% in localcurrency terms and +0.3% in US dollar terms. Forecast in line with Q315.